NK cells

Phase 2Cell therapy

SSouthwest Hospital, China

NK cells is one of 140 biologic programs targeting Neuroblastoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

139

Competitors

Pipeline

Status by Indication[3][1]

Indication

NeuroblastomaActive, not recruiting

Acute Myeloid LeukemiaNot yet recruiting

Solid TumorNot yet recruiting

NSCLC (advanced Non-Small Cell Lung Cancer)Not yet recruiting

Natural Killer CellRecruiting

NK CellRecruiting

NeuroblastomaPhase 1

Active, not recruiting

Acute Myeloid LeukemiaPhase 2

Not yet recruiting

Solid TumorPhase 1

Not yet recruiting

NSCLC (advanced Non-Small Cell Lung Cancer)Preclinical

Not yet recruiting

Natural Killer CellPhase 1

Recruiting

NK CellPhase 1

Recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

NK cells

SSouthwest Hospital, China

Phase 2

1 2

Fludara

Sanofi

Preclinical

2 3

DATROWAY

Daiichi Sankyo

Preclinical

1 4

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

3 5

Navmi

SSummit Therapeutics

Preclinical

1 6

Paxil

SSebela Pharmaceuticals Development LLC

Preclinical

1 7

Ifinatamab Deruxtecan

Daiichi Sankyo

Preclinical

1 8

Tulmimetostat

Novartis

Preclinical

1 9

Carboplatin AUC-5

Merck & Co.

Preclinical

1 10

MHB036C

MMinghui Pharmaceutical (Hangzhou) Ltd

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Neuroblastoma

NCT02573896

Q2 2028

Phase 1/2Not yet recruiting

Acute Myeloid Leukemia

NCT05319249

Phase 1Recruiting

Acute Myeloid Leukemia

NCT05834244

Q3 2028

Phase 1Not yet recruiting

Solid Tumor

NCT07784777

Q2 2029

PreclinicalNot yet recruiting

NSCLC (advanced Non-Small Cell Lung Cancer)

NCT07551778

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia2 trials

A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT05834244·32 enrolled

Natural Killer Cell Immunotherapy in Combination With PARP-inhibition in Acute Myeloid Leukemia

Not yet recruiting·GGerman Cancer Research Center·Phase 1/2·NCT05319249·54 enrolled

Neuroblastoma2 trials

Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT02650648·85 enrolled

Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells

Active, not recruiting·NNew Approaches to Neuroblastoma Therapy Consortium·Phase 1·NCT02573896·13 enrolled

COVID-191 trial

NK Cells Treatment for COVID-19

Completed·HHenan Medical University·Phase 1·NCT04280224·2 enrolled

Leukemia1 trial

Adoptive Immunotherapy of High Risk Acute Myeloblastic Leukemia Patients Using Haploidentical Kir Ligand-mismatched Natural Killer Cells

Unknown status·UUniversity of Bologna·Phase 1·NCT00799799·15 enrolled

Myeloid Diseases1 trial

NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT01370213·25 enrolled

17 more indications

Natural Killer Cell1 trial

Phase 1 Study of Locoregional Injections of Ex Vivo Expanded Natural Killer Cells

Recruiting·NNationwide Children's Hospital·Phase 1·NCT04254419·18 enrolled

Myelodysplastic Syndrome1 trial

Natural Killer Cells in Acute Leukaemia and Myelodysplastic Syndrome

Unknown status·NNational University Hospital, Singapore·Phase 1·NCT02123836·20 enrolled

Advanced Malignancies1 trial

NK Cells Infusion for Advanced Malignancies

Unknown status·—·Phase 1·NCT03619954·50 enrolled

Primary Peritoneal Cancer1 trial

Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Completed·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT02118285·2 enrolled

Non-Small Cell Lung Cancer1 trial

A Clinical Research of NK Cell Infusion Combined With Chemotherapy in the Treatment of Non-small Cell Lung Cancer

Unknown status·SSouthwest Hospital, China·Phase 2·NCT02734524·104 enrolled

Immunotherapy1 trial

Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy With NK Cells in High-risk AML

Terminated·TTechnische Universität Dresden·Phase 2·NCT02229266·1 enrolled

Hepatocellular Carcinoma1 trial

By Using Adoptive Transfer of Autologous NK Cells to Prevent Recurrence of Hepatocellular Carcinoma After Curative Therapy

Unknown status·SSouthwest Hospital, China·Phase 2·NCT02725996·140 enrolled

Myelopathy1 trial

Immunotherapy of Natural Killer(NK) Cells in Human T Lymphotropic Virus Type 1(HTLV-1) Associated Myelopathy(HAM)

Unknown status·TThe Second Affiliated Hospital of Fujian Medical University·Phase 1·NCT02961712·15 enrolled

Pancreatic Cancer1 trial

Combination of Irreversible Electroporation and NK Immunotherapy for Advanced Pancreatic Cancer

Completed·FFuda Cancer Hospital, Guangzhou·Phase 1/2·NCT02718859·60 enrolled

Lung Cancer1 trial

NK Cell-based Immunotherapy as Maintenance Therapy for Small-Cell Lung Cancer.

Unknown status·Jjiuwei cui·Phase 2·NCT03410368·120 enrolled

Lung Adenocarcinoma1 trial

Effect of NK Cell Immunotherapy on Advanced Lung Adenocarcinoma Adenocarcinoma With EGFR Mutation

Unknown status·SShenzhen Fifth People's Hospital·Phase 1·NCT03662477·10 enrolled

Breast Cancer1 trial

A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020

Terminated·VVall d'Hebron Institute of Oncology·Phase 1·NCT05385705·2 enrolled

Chronic Myeloid Leukemia (CML)1 trial

Safety and the Anti- Tumor Effects of Escalating Doses of Adoptively Infused Ex Vivo Expanded Autologous Natural Killer (NK) Cells Against Metastatic Cancers or Hematological Malignancies Sensitized to NK-TRAIL Cytotoxicity With Bortezomib

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 1·NCT00720785·35 enrolled

Colorectal Cancer1 trial

Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")

Recruiting·MM.D. Anderson Cancer Center·Preclinical·NCT07411599·28 enrolled

NSCLC (Advanced Non-small Cell Lung Cancer)1 trial

An Exploratory Clinical Study to Evaluate the Safety and Efficacy of Allogeneic NK Cell Injection Combined With Standard Maintenance Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors

Not yet recruiting·BBOE Technology Group Co., Ltd.·Preclinical·NCT07551778·42 enrolled

Solid Tumor1 trial

An Open-Label, Dose-Escalation Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of NK Cell Injection in the Treatment of Advanced Solid Tumors

Not yet recruiting·BBOE Technology Group Co., Ltd.·Phase 1·NCT07784777·9 enrolled

NK Cell1 trial

A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT07579208·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 24 trial records for NK cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NK cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NK cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Southwest Hospital, China company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: SSouthwest Hospital, China

NK cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2028

Q3 2028

Q2 2029

Trials by Indication[1]

Acute Myeloid Leukemia2 trials

Neuroblastoma2 trials

COVID-191 trial

Leukemia1 trial

Myeloid Diseases1 trial

Natural Killer Cell1 trial

Myelodysplastic Syndrome1 trial

Advanced Malignancies1 trial

Primary Peritoneal Cancer1 trial

Non-Small Cell Lung Cancer1 trial

Immunotherapy1 trial

Hepatocellular Carcinoma1 trial

Myelopathy1 trial

Pancreatic Cancer1 trial

Lung Cancer1 trial

Lung Adenocarcinoma1 trial

Breast Cancer1 trial

Chronic Myeloid Leukemia (CML)1 trial

Colorectal Cancer1 trial

NSCLC (Advanced Non-small Cell Lung Cancer)1 trial

Solid Tumor1 trial

NK Cell1 trial

References

Drug Info

Quick Facts

Related News